tiprankstipranks
Intellia Therapeutics Inc (CH:38I)
NASDAQ:38I
Switzerland Market
38I
Intellia Therapeutics
RESEARCH TOOLSreports

Intellia Therapeutics (38I) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

38I Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
8 Buy
8 Hold
2 Sell
Based on 18 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

38I Stock 12 Month Forecast

Average Price Target

$17.06
Based on 18 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $17.06 with a high forecast of $39.69 and a low forecast of $6.48. The average price target represents a ― change from the last price of ―.
eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
Highest Price Target$39.69Average Price Target$17.06Lowest Price Target$6.48
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:38I
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF39.69
Buy
―
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on CH:38I
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF9.72
Hold
―
Reiterated
06/15/26
Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
William Blair Analyst forecast on CH:38I
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/15/26
Analysts' Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)
H.C. Wainwright Analyst forecast on CH:38I
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF20.25
Buy
―
Reiterated
06/15/26
Intellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target
Bank of America Securities Analyst forecast on CH:38I
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF15.39
Hold
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: enGene Holdings (NASDAQ: ENGN) and Intellia Therapeutics (NASDAQ: NTLA)
TD Cowen Analyst forecast on CH:38I
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/14/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)
Goldman Sachs Analyst forecast on CH:38I
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF7.29
Sell
―
Reiterated
06/14/26
Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed
JonesTrading Analyst forecast on CH:38I
Debanjana Chatterjee
JonesTrading
JonesTrading
CHF23.49
Buy
―
Reiterated
05/27/26
Intellia Therapeutics: Buy Rating Reiterated on De-Risked HAE and ATTR Pipelines; $29 DCF-Based Price Target Maintained
Morgan Stanley Analyst forecast on CH:38I
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF12.15
Hold
―
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), TriSalus Life Sciences (NASDAQ: TLSI) and Fractyl Health, Inc. (NASDAQ: GUTS)
J.P. Morgan Analyst forecast on CH:38I
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF6.48
Sell
―
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Bernstein Analyst forecast on CH:38I
William Pickering
Bernstein
Bernstein
CHF10.53→CHF13.77
Hold
―
Assigned
05/13/26
Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein
Wells Fargo Analyst forecast on CH:38I
Yanan Zhu
Wells Fargo
Wells Fargo
CHF12.15
Hold
―
Reiterated
05/12/26
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
RBC Capital Analyst forecast on CH:38I
Luca Issi
RBC Capital
RBC Capital
CHF12.15
Hold
―
Reiterated
05/11/26
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Citizens JMP Analyst forecast on CH:38I
Silvan Tuerkcan
Citizens JMP
Citizens JMP
CHF22.68→CHF24.3
Buy
―
Reiterated
04/28/26
Intellia Therapeutics price target raised to $30 from $28 at CitizensIntellia Therapeutics price target raised to $30 from $28 at Citizens
Evercore ISI Analyst forecast on CH:38I
Jonathan Miller
Evercore ISI
Evercore ISI
CHF12.96
Hold
―
Reiterated
04/28/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Intellia Therapeutics (NASDAQ: NTLA) and Incyte (NASDAQ: INCY)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on CH:38I
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF39.69
Buy
―
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on CH:38I
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF9.72
Hold
―
Reiterated
06/15/26
Wedbush Remains a Hold on Intellia Therapeutics (NTLA)
William Blair Analyst forecast on CH:38I
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/15/26
Analysts' Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)
H.C. Wainwright Analyst forecast on CH:38I
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF20.25
Buy
―
Reiterated
06/15/26
Intellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target
Bank of America Securities Analyst forecast on CH:38I
Alec Stranahan
Bank of America Securities
Bank of America Securities
CHF15.39
Hold
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: enGene Holdings (NASDAQ: ENGN) and Intellia Therapeutics (NASDAQ: NTLA)
TD Cowen Analyst forecast on CH:38I
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/14/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)
Goldman Sachs Analyst forecast on CH:38I
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF7.29
Sell
―
Reiterated
06/14/26
Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed
JonesTrading Analyst forecast on CH:38I
Debanjana Chatterjee
JonesTrading
JonesTrading
CHF23.49
Buy
―
Reiterated
05/27/26
Intellia Therapeutics: Buy Rating Reiterated on De-Risked HAE and ATTR Pipelines; $29 DCF-Based Price Target Maintained
Morgan Stanley Analyst forecast on CH:38I
Terence Flynn
Morgan Stanley
Morgan Stanley
CHF12.15
Hold
―
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), TriSalus Life Sciences (NASDAQ: TLSI) and Fractyl Health, Inc. (NASDAQ: GUTS)
J.P. Morgan Analyst forecast on CH:38I
Brian Cheng
J.P. Morgan
J.P. Morgan
CHF6.48
Sell
―
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Bernstein Analyst forecast on CH:38I
William Pickering
Bernstein
Bernstein
CHF10.53→CHF13.77
Hold
―
Assigned
05/13/26
Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein
Wells Fargo Analyst forecast on CH:38I
Yanan Zhu
Wells Fargo
Wells Fargo
CHF12.15
Hold
―
Reiterated
05/12/26
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
RBC Capital Analyst forecast on CH:38I
Luca Issi
RBC Capital
RBC Capital
CHF12.15
Hold
―
Reiterated
05/11/26
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Citizens JMP Analyst forecast on CH:38I
Silvan Tuerkcan
Citizens JMP
Citizens JMP
CHF22.68→CHF24.3
Buy
―
Reiterated
04/28/26
Intellia Therapeutics price target raised to $30 from $28 at CitizensIntellia Therapeutics price target raised to $30 from $28 at Citizens
Evercore ISI Analyst forecast on CH:38I
Jonathan Miller
Evercore ISI
Evercore ISI
CHF12.96
Hold
―
Reiterated
04/28/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Intellia Therapeutics (NASDAQ: NTLA) and Incyte (NASDAQ: INCY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months
Mani ForooharLeerink Partners
Success Rate
15/39 ratings generated profit
38%
Average Return
+5.85%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of +5.85% per trade.
1 Year
Gena WangBarclays
Success Rate
11/26 ratings generated profit
42%
Average Return
-8.26%
Copying Gena Wang's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of -8.26% per trade.
2 Years
Gena WangBarclays
Success Rate
10/26 ratings generated profit
38%
Average Return
-16.06%
Copying Gena Wang's trades and holding each position for 2 Years would result in 38.46% of your transactions generating a profit, with an average return of -16.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

38I Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
6
10
13
10
Buy
3
5
4
5
5
Hold
13
22
15
19
13
Sell
0
1
2
4
4
Strong Sell
0
0
0
0
0
total
18
34
31
41
32
In the current month, 38I has received 15 Buy Ratings, 13 Hold Ratings, and 4 Sell Ratings. 38I average Analyst price target in the past 3 months is 17.06.
Each month's total comprises the sum of three months' worth of ratings.

38I Financial Forecast

38I Earnings Forecast

Next quarter’s earnings estimate for 38I is -$0.64 with a range of -$0.75 to -$0.50. The previous quarter’s EPS was -$0.64. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.
Next quarter’s earnings estimate for 38I is -$0.64 with a range of -$0.75 to -$0.50. The previous quarter’s EPS was -$0.64. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Sales Forecast

Next quarter’s sales forecast for 38I is $10.48M with a range of $0.00 to $13.11M. The previous quarter’s sales results were $11.96M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.
Next quarter’s sales forecast for 38I is $10.48M with a range of $0.00 to $13.11M. The previous quarter’s sales results were $11.96M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Stock Forecast FAQ

What is CH:38I’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics Inc’s 12-month average price target is 17.06.
    What is CH:38I’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:38I, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Intellia Therapeutics Inc a Buy, Sell or Hold?
        Intellia Therapeutics Inc has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 8 hold ratings and 2 sell ratings.
          What is Intellia Therapeutics Inc’s share price target?
          The average share price target for Intellia Therapeutics Inc is 17.06. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $39.69 ,and the lowest forecast is $6.48. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Intellia Therapeutics Inc?
            Intellia Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
              How can I buy shares of Intellia Therapeutics Inc?
              To buy shares of CH:38I, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.